Linking Atrial Fibrillation with Alzheimer's Disease: Epidemiological, Pathological, and Mechanistic Evidence

Masafumi Ihara1, Kazuo Washida1

  • 1Department of Neurology, National Cerebral and Cardiovascular Center, Japan.

Insights

Atrial fibrillation (AF) may increase Alzheimer's disease (AD) risk by 1.5- to 2.5-fold, potentially through chronic cerebral hypoperfusion. Treatments like catheter ablation show promise for managing AD in AF patients.

Area of Science:

  • Neurology
  • Cardiology
  • Geriatrics

Background:

  • Atrial fibrillation (AF) is a known risk factor for vascular dementia.
  • The relationship between Alzheimer's disease (AD) and AF is not well understood.
  • Epidemiological studies suggest AF increases AD risk by 1.5- to 2.5-fold.

Purpose of the Study:

  • To explore the potential mechanisms linking AF and AD.
  • To investigate the role of chronic cerebral hypoperfusion in AD neuropathology.
  • To assess the impact of AF treatments on AD incidence and progression.

Main Methods:

  • Review of epidemiological and neuropathological studies.
  • Analysis of proposed mechanisms involving cerebral hypoperfusion, amyloid-β (Aβ) and tau pathology.
  • Examination of observational data on AF treatments (catheter ablation, rate/rhythm control).

Main Results:

  • Chronic cerebral hypoperfusion from AF may exacerbate Aβ and tau pathologies.
  • Neuropathological studies suggest vascular factors, not direct AF-AD links, may mediate the association.
  • Observational data indicate catheter ablation may reduce AD incidence in AF patients.
  • Rate-control strategies may slow cognitive decline in AF patients with cognitive impairment.

Conclusions:

  • Vascular neuropathology may mediate the link between AF and AD.
  • AF management, including anticoagulation and rhythm/rate control, may offer benefits for AD patients.
  • Further research is needed to elucidate the precise mechanisms connecting AF and AD.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...